Drugs and Effects | Study Type | Species | Reference |
---|---|---|---|
Calcium channel blockers that reverse MDR increased levels of anthracyclines and potentiated cardiotoxicity | In vitro | Sprague-Dawley rat | Santostasi et al. (1991) |
Mice treated with verapamil and doxorubicin had a lower survival rate, higher incidence and severity of degenerative changes in cardiac tissue, and a higher peak concentration of doxorubicin in the heart compared with mice treated with doxorubicin alone | In vivo | (BALB/c × DBA/2)F1 mouse | Sridhar et al. (1992) |
Cyclosporin A increased doxorubicin concentration in heart | In vivo | Crl/CD BR rat and CD2F1/Crl BR mouse | Colombo et al. (1994) |
Increase in cardiac levels of doxorubicin when cyclosporin A administered and higher incidence and severity of myocardial damage | In vivo | SCID mouse | Bellamy et al. (1995) |
Greater area under the curve of doxorubicin in the heart when combined with PSC 833 (cyclosporin A analog) | In vivo | CDF1 mouse | Gonzalez et al. (1995) |
When myocardial cells incubated with daunorubicin and MDR-reversing agent (verapamil, PSC 833, or S9788), a moderate, but significant, intracellular increase of [3H]daunorubicin was obtained | In vitro | Wistar newborn rat ventricular myocytes | Cayre et al. (1996) |
Doxorubicin concentration increased in heart of mice pretreated with PSC 833 | In vivo | BDF1 mouse | Colombo et al. (1996a) |
Increased cardiotoxicity of doxorubicin in the presence of amiodarone | In vitro | Neonatal Wistar rat | Estevez et al. (2000) |
Myocardial uptake of idarubicin (anticancer) was increased by verapamil | Ex vivo | Sprague-Dawley rat | Kang and Weiss (2001) |
Higher tissue concentration of etoposide in heart following cyclosporin A administration | In vivo | Wistar rat | Cárcel-Trullols et al. (2004) |
Pretreatment with paclitaxel induced a significant increase in epidoxorubicin in the heart | In vivo | CDF1 mouse | Colombo et al. (1996b) |
Reduction of heart contractility and development of congestive heart failure were obtained with doxorubicin and paclitaxel combination | In vivo | Human | Gianni et al. (1995) |
Patient received verapamil and clarithromycin and developed bradycardia and hypotension; withdrawal of verapamil resulted in resolution of symptoms | In vivo | Human | Kaeser et al. (1998) |
Patient was taking verapamil and developed bradycardia while receiving erythromycin and clarithromycin | In vivo | Human | Steenbergen and Stauffer (1998) |
Following coadministration of erythromycin and verapamil, the patient had atrioventricular block and QT interval prolongation | In vivo | Human | Goldschmidt et al. (2001) |
S9788, 6-[4-[2,2-di(4-fluorophenyl)-ethylamino]-1-piperidinyl]-N,N′-di-2-propenyl-1,3,5-triazine-2,4-diamine